The FDA accepted a resubmitted new drug application for reproxalap, a first-in-class investigational topical therapy for dry ...

For millions of self-employed Americans, the Affordable Care Act’s (ACA) open enrollment period is one of the most important ...

Here’s a breakdown of several provisions of the One Big Beautiful Bill that will significantly reshape how benefits advisors guide clients on plan design, compliance and benefit strategy.

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...

Infuse for TLIF initially received FDA breakthrough device designation in April 2024. A new indication could expand treatment ...